WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&a
Jul 11, 2008
July 11, 2008 - Shanghai, China - WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today proudly announced that it has won the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology.
Frost & Sullivan Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. The Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology is awarded to the company that has demonstrated commendable success in forming strategic partnerships with overseas clients for outsourced laboratory and research manufacturing services in drug discovery and development in pharmaceuticals and biotechnology.
Quality of scientists and personnel, service portfolio, quality of services, speed of service delivery, cost competitiveness, past experience and referrals are the selection criteria that Frost & Sullivan used in its research. According to Frost & Sullivan, WuXi has excelled in the delivery of high-quality services in a timely manner and at competitive costs through a team of proficient scientists supported by world-class management.
"Until January, 2008, WuXi PharmaTech had provided services to more than 700 global clients, with coverage of pharmaceutical, biotechnology and medical devices. High proportion of repeat and referral customers is a testament to its focus on customer satisfaction and operational excellence," said Frost & Sullivan Leader of China Healthcare Operation Mr. Xuchao Hou. "The main contributing factor to this impressive reward has been exceptional leverage of China's advantage, high technical expertise and world class management, robust expanding service portfolio, adherence to strict quality control and commitment to intellectual property rights protection."
"We are honored to receive this prestigious award in recognition of our research driven, customer focus and continuous improvement practices in helping our customers to improve the success of research and shorten the time of development," commented Dr. Ge Li. "We will continue expanding our service capabilities and capacity to better serve our global pharmaceutical and medical device customers."
About Frost & Sullivan
Frost & Sullivan, the Global Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.frost.com.
About WuXi PharmaTech (Cayman) Inc.
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. The operating subsidiaries of WuXi PharmaTech are known as WuXi AppTec. For more information, please visit: www.wuxiapptec.com.